Validation of human apoB and apoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research

Journal of Cardiovascular Translational Research

Volumn 4, Issue 3, 2011, Pages 373-383

  Chen, Zhu ^a   Strack, Alison M ^a   Stefanni, Alice C ^a   Chen, Ying ^a   Wu, Weizhen ^a   Pan, Yi ^a   Urosevic Price, Olga ^a   Wang, Li ^a   McLaughlin, Theresa ^a   Geoghagen, Neil ^a   Lassman, Michael E ^a   Roddy, Thomas P ^a   Wong, Kenny K ^a   Hubbard, Brian K ^a   Flattery, Amy M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

apoAI; apoB; Immunoturbidity assays; Lipids; Non human primate

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

ARTICLE; ASSAY; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HAPLORHINI; IMMUNOTURBIDITY ASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIMATE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; VALIDATION STUDY;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CALIBRATION; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAPLORHINI; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOASSAY; MASS SPECTROMETRY; NEPHELOMETRY AND TURBIDIMETRY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SIMVASTATIN;

CERCOPITHECUS AETHIOPS; MACACA FASCICULARIS; MACACA MULATTA; PRIMATES; RODENTIA;

EID: 79960554186     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-011-9264-4     Document Type: Article

References (38)

1. Kathiresan, S., Otvos, J. D., Sullivan, L. M., Keyes, M. J., Schaefer, E. J., Wilson, P. W., et al. (2006). Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation, 113, 20-29. (Pubitemid 43958484)
2. Barter, P. J., Ballantyne, C. M., Carmena, R., Castro Cabezas, M., Chapman, M. J., Couture, P., et al. (2006). Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. Journal of Internal Medicine, 259, 247-258.
3. Contois, J. H., McNamara, J. R., Lammi-Keefe, C. J., Wilson, P. W., Massov, T., & Schaefer, E. J. (1996). Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clinical Chemistry, 42, 515-523. (Pubitemid 26111868)
4. Contois, J., McNamara, J. R., Lammi-Keefe, C., Wilson, P. W., Massov, T., & Schaefer, E. J. (1996). Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clinical Chemistry, 42, 507-514. (Pubitemid 26111867)
5. Walldius, G., & Jungner, I. (2007). Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Current Opinion in Cardiology, 22, 359-367. (Pubitemid 46897289)
6. Strong, J. P., & McGill, H. C., Jr. (1967). Diet and experimental atherosclerosis in baboons. The American Journal of Pathology, 50, 669-690.
7. Clarkson, T. B., Hamm, T. E., Bullock, B. C., & Lehner, N. D. (1976). Atherosclerosis in old world monkeys. Primates in Medicine, 9, 66-89.
8. Rudel, L. L., Bond, M. G., & Bullock, B. C. (1985). LDL heterogeneity and atherosclerosis in nonhuman primates. Annals of the New York Academy of Sciences, 454, 248-253. (Pubitemid 16198857)
9. Rudel, L. L. (1997). Genetic factors influence the atherogenic response of lipoproteins to dietary fat and cholesterol in nonhuman primates. Journal of the American College of Nutrition, 16, 306-312. (Pubitemid 27333033)
10. Rudel, L. L., Reynolds, J. A., & Bullock, B. C. (1981). Nutritional effects on blood lipid and HDL cholesterol concentrations in two subspecies of African green monkeys (Cercopithecus aethiops). Journal of Lipid Research, 22, 278-286. (Pubitemid 11125132)
11. Mahley, R. W., Innerarity, T. L., Rall, S. C., Jr., & Weisgraber, K. H. (1984). Plasma lipoproteins: apolipoprotein structure and function. Journal of Lipid Research, 25, 1277-1294. (Pubitemid 15150638)
12. Law, A., & Scott, J. (1990). A cross-species comparison of the apolipoprotein B domain that binds to the LDL receptor. Journal of Lipid Research, 31, 1109-1120. (Pubitemid 20197813)
13. O'Huigin, C., Chan, L., & Li, W. H. (1990). Cloning and sequencing of bovine apolipoprotein A-I cDNA and molecular evolution of apolipoproteins A-I and B-100. Molecular Biology and Evolution, 7, 327-339.
14. Collet, X., Marcel, Y. L., Tremblay, N., Lazure, C., Milne, R. W., Perret, B., et al. (1997). Evolution of mammalian apolipoprotein A-I and conservation of antigenicity: correlation with primary and secondary structure. Journal of Lipid Research, 38, 634-644. (Pubitemid 27194915)
15. Siedel, J., Schiefer, S., Rosseneu, M., Bergeaud, R., De Keersgieter, W., Pautz, B., et al. (1988). Immunoturbidimetric method for routine determinations of apolipoproteins A-I, A-II, and B in normo-and hyperlipemic sera compared with immunonephelometry. Clinical Chemistry, 34, 1821-1825.
16. Rifai, N., & King, M. E. (1986). Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clinical Chemistry, 32, 957-961. (Pubitemid 17021156)
17. Naito, H. K. (1988). Reliability of lipid, lipoprotein, and apolipoprotein measurements. Clinical Chemistry, 34, B84-B94.
18. Albers, J. J., Marcovina, S. M., & Kennedy, H. (1992). International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clinical Chemistry, 38, 658-662.
19. Marcovina, S. M., Albers, J. J., Kennedy, H., Mei, J. V., Henderson, L. O., & Hannon, W. H. (1994). International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clinical Chemistry, 40, 586-592.
20. Borque, L., Maside, C., Rus, A., & Del Cura, J. (1993). Automated determination of apolipoproteins A-I and B with an improved immunoturbidimetric assay using Boehringer Mannheim and Hitachi analyzer systems. Clinical Biochemistry, 26, 471-476.
21. Dallinga-Thie, G. M., Berk, P., II, Bootsma, A. H., & Jansen, H. (2004). Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care, 27, 1358-1364. (Pubitemid 38679983)
22. Dullaart, R. P., Perton, F., Sluiter, W. J., de Vries, R., & van Tol, A. (2008). Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. The Journal of Clinical Endocrinology and Metabolism, 93, 4860-4866.
23. Szanto, A., Harangi, M., Seres, I., Paragh, G., & Zeher, M. (2010). Decreased human paraoxonase-1 activity in patients with Sjogren's syndrome. International Immunology, 22, 605-609.
24. Sniderman, A., Teng, B., & Jerry, M. (1975). Determination of B protein of low density lipoprotein directly in plasma. Journal of Lipid Research, 16, 465-467.
25. Rader, D. J., Davidson, M. H., Caplan, R. J., & Pears, J. S. (2003). Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. American journal of cardiology, 91, 20C-23C. discussion 23C-24C.
26. Quinet, E. M., Basso, M. D., Halpern, A. R., Yates, D. W., Steffan, R. J., Clerin, V., et al. (2009). LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. Journal of Lipid Research, 50, 2358-2370.
27. Ito, B. R., Zhang, B. H., Cable, E. E., Song, X., Fujitaki, J. M., MacKenna, D. A., et al. (2009). Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. British Journal of Pharmacology, 156, 454-465.
28. Schonfeld, G., Lees, R. S., George, P. K., & Pfleger, B. (1974). Assay of total plasma apolipoprotein B concentration in human subjects. Journal of Clinical Investigation, 53, 1458-1467.
29. Karlin, J. B., Juhn, D. J., Fless, G., Scanu, A. M., & Rubenstein, A. H. (1978). Measurment of rhesus monkey (Macaca mulatta) apolipoprotein B in serum by radioimmunoassay: comparison of immunoreactivities of rhesus and human low density lipoproteins. Journal of Lipid Research, 19, 197-206. (Pubitemid 8288800)
30. Pape, M. E., Castle, C. K., Murray, R. W., Funk, G. M., Hunt, C. E., Marotti, K. R., et al. (1991). Apo B metabolism in the cynomolgus monkey: evidence for post-transcriptional regulation. Biochimica et Biophysica Acta, 1086, 326-334.
31. Mahley, R. W., & Innerarity, T. L. (1983). Lipoprotein receptors and cholesterol homeostasis. Biochimica et Biophysica Acta, 737, 197-222. (Pubitemid 13086955)
32. Koritnik, D. L., & Rudel, L. L. (1983). Measurement of apolipoprotein A-I concentration in nonhuman primate serum by enzyme-linked immunosorbent assay (ELISA). Journal of Lipid Research, 24, 1639-1645. (Pubitemid 14222142)
33. Brewer, H. B., Jr., Lux, S. E., Ronan, R., & John, K. M. (1972). Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. Proceedings of the National Academy of Sciences of the United States of America, 69, 1304-1308.
34. Cheung, M. C., & Albers, J. J. (1979). Distribution of cholesterol and apolipoprotein A-I and A-II in human high density lipoprotein subfractions separated by CsCl equilibrium gradient centrifugation: evidence for HDL subpopulations with differing A-I/A-II molar ratios. Journal of Lipid Research, 20, 200-207. (Pubitemid 9150667)
35. Myerson, M., Ngai, C., Jones, J., Holleran, S., Ramakrishnan, R., Berglund, L., et al. (2005). Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. Journal of Lipid Research, 46, 2735-2744. (Pubitemid 43107486)
36. Ballantyne, C. M., Bertolami, M., Hernandez Garcia, H. R., Nul, D., Stein, E. A., Theroux, P., et al. (2006). Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. American Heart Journal, 151(975), e1-e9.
37. Simon, J. A., Lin, F., Hulley, S. B., Blanche, P. J., Waters, D., Shiboski, S., et al. (2006). Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. The American Journal of Cardiology, 97, 843-850.
38. Sparrow, C. P., Burton, C. A., Hernandez, M., Mundt, S., Hassing, H., Patel, S., et al. (2001). Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 115-121. (Pubitemid 32061935)